CVRx (CVRX) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $13.4 million, up 27% year-over-year, driven by strong U.S. heart failure business and Barostim adoption, with increased physician and patient awareness.

• Net loss widened to $13.1 million ($0.57/share) from $9.0 million ($0.43/share) last year, mainly due to higher SG&A and interest expenses.

• U.S. active implanting centers rose to 208 from 159 year-over-year; sales territories expanded to 45 from 35.

• Barostim received favorable Medicare inpatient payment reassignment, increasing average payment to ~$43,000 as of October 2024, and approval of Category 1 CPT codes effective January 2026.

• Expanded leadership team and board, enhancing commercialization and financial expertise.

Financial highlights

• U.S. revenue reached $12.3 million, up 28% year-over-year; U.S. heart failure revenue was $12.2 million on 391 units (vs. 303 units last year).

• European revenue was $1.1 million, up 15% year-over-year, with 56 revenue units.

• Gross profit was $11.1 million; gross margin was 83% (vs. 84% last year).

• SG&A expenses increased 38% to $21.6 million, mainly due to higher compensation and stock-based expenses.

• Cash and cash equivalents stood at $100.2 million as of September 30, 2024.

Outlook and guidance

• Full-year 2024 revenue expected between $50.5 million and $51.5 million; Q4 2024 revenue guidance is $14.5–$15.5 million.

• Full-year gross margin expected between 83% and 85%; operating expenses projected at ~$100 million.

• Management expects continued operating losses and negative cash flows as investments in commercialization and R&D persist.

• Existing cash and equivalents are expected to fund operations for at least three years.

• Focus on expanding U.S. sales force, increasing Barostim adoption, and pursuing expanded indications.